Company intelligence / Profile preview

Alper Biotech LLC

Rockville, Maryland, United States

Ownership: Private
Development stage: Dissolved

Overview

Research from Alper Biotech has led to the development and characterization of novel monoclonal antibodies targeting GMF-beta and alpha-actinin–4, showing significant potential as diagnostic biomarkers for breast carcinoma. Published abstracts report promising results in identifying primary and metastatic breast cancer using these markers, but there are no registered clinical trials or approved products yet.

Therapeutic areas: Oncology
Modalities: Monoclonal antibodies
Industry: Protein Biomarker Diagnostics

Beyond the preview

Go deeper on Alper Biotech LLC.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alper Biotech LLC.

Explore the full profile